NCT00019396 2024-03-04
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
17 trialsNCT00020267 2024-03-04
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03617328 2024-02-06
Mel-65
University of Virginia
Phase 1/2 Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00019682 2017-11-20
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT01585350 2016-08-12
MEL58
University of Virginia
Phase 1 Completed
NCT00923195 2015-10-28
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089063 2015-04-15
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003224 2014-11-20
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Virginia
Phase 1 Completed
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00112216 2013-04-24
Immunotherapy of Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT00006243 2013-01-25
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase NA Completed
NCT00001832 2012-12-21
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00059475 2012-10-23
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00273910 2012-10-19
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00080353 2012-06-14
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed